GlassScriptPhysician profile
Rumaisa Hameed
NPI 1023447349
$1,377.16
in general payments reported to CMS, 2019-2025
17 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.95 · 2020: $99.00 · 2022: $79.99 · 2023: $99.95 · 2024: $75.92 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Long Term Medical Supply Or Device Loan: $199 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.87 |
| Long Term Medical Supply Or Device Loan | $199.40 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $418.77 | 2019-2025 | Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $227.90 | 2025 | |
| Janssen Biotech, INC. | $155.62 | 2023-2025 | Darzalex, Akeega, Rybrevant |
| Merck Sharp & Dohme LLC | $63.80 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $60.17 | 2025 | |
| Tersera Therapeutics LLC | $52.61 | 2025 | Zoladex |
| Puma Biotechnology, INC. | $49.74 | 2025 | |
| Lilly USA, LLC | $46.61 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $45.80 | 2025 | Blenrep, Ojjaara |
| Eisai INC. | $44.85 | 2025 | |
| Sumitomo Pharma America, INC. | $43.02 | 2025 | Orgovyx |
| Caris Mpi, INC. | $40.95 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $29.28 | 2025 | Tevimbra |
| Genentech USA, INC. | $26.20 | 2025 | Itovebi |
| Pfizer INC. | $25.62 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.03 | 2025 | Vyloy |
| Deciphera Pharmaceuticals INC. | $22.19 | 2024 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rumaisa Hameed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.